Combination Therapy for Advanced Renal Cell Cancer
Author Information
Author(s): Allen M J, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore M E
Primary Institution: Royal Marsden Hospital, London, UK
Hypothesis
The study aimed to assess the activity of alpha-interferon, interleukin-2, and 5-fluorouracil administered by protracted venous infusion compared to bolus injection.
Conclusion
The combination therapy showed significant activity in advanced renal cell cancer with manageable toxicity.
Supporting Evidence
- 31% of patients had a response to the treatment.
- Three patients achieved complete response and remain progression-free for over 14 months.
- The overall median survival was 11 months.
- 54% response rate was observed in evaluable patients with poor prognostic features.
Takeaway
Doctors tested a new way to give medicine to help people with kidney cancer, and it worked pretty well for many of them.
Methodology
Patients received interleukin-2 and alpha-interferon according to a specific schedule, along with protracted venous infusion of 5-fluorouracil.
Limitations
Toxicity was significant, with some patients unable to complete treatment due to side effects.
Participant Demographics
42 out of 55 patients were of moderate or poor prognosis.
Statistical Information
Confidence Interval
95% CI = 19–45%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website